Vistin Pharma plans to raise up to Nkr300m ($38.82m) in gross proceeds through a private placement of shares of its common stock.
The company will divest 26,785,715 shares to Norwegian and international investors and has received significant pre-commitments.
The proceeds are intended to be used for setting up energy trading business and trading activities.
Vistin Pharma is a Norway-based active pharmaceutical ingredients (API) provider.
Shenzhen Neptunus Bioengineering is planning to make a public offering of short-term financing bonds to raise CNY2bn ($315.58m) in gross proceeds.
The proceeds are intended to be used to repay loans from financial institutions and to supplement working capital.
Shenzhen Neptunus manufactures and distributes pharmaceutical products.
China Traditional Chinese Medicine Holdings plans to raise approximately HK$2.67bn ($341.3m) in gross proceeds through the private placement of shares.
The company will place 604.3 million shares priced at HK$4.43 ($0.56) a share, as part of the transaction.
Ping An Life Insurance Company of China has subscribed to the placement.
The proceeds are intended to be used to expand the company’s traditional Chinese medicine business, as well as to make acquisitions, repay debts, supplement working capital, and for research and development (R&D).
China Traditional Chinese Medicine Holdings is based in Hong Kong.